Guillain-?Barr Syndrome is a rare condition in which a person's immune system attacks the peripheral nerves. People affected suffer from muscle weakness and paralysis. A research team led by ETH ...
Guillain-Barré Syndrome (GBS) is a rare neuromuscular condition that can cause rapid paralysis. Diagnosing GBS is challenging, and misdiagnosis can lead to delayed treatment and potentially long-term ...
Hansa Biopharma, “Hansa”, today announced positive high-level data from the 15-HMedIdeS-09 phase 2 trial that demonstrated imlifidase was safe and well tolerated when administered prior to standard of ...
Doctors in Bengaluru report a 15–20% rise in Guillain-Barré Syndrome since the Covid pandemic, with younger patients ...
Annexon, Inc. (ANNX) was able to achieve positive results from its phase 3 study for the treatment of patients with Guillain-Barré syndrome [GBS]. Matter of fact, it noted that a lower dose of its ...
Annexon (ANNX) announced topline results from a real-world evidence study supporting ANX005 as a potential treatment for Guillain-Barre Syndrome. GBS is a rapid-onset and acute neuromuscular disease ...
As it advances a monoclonal antibody targeting Guillain-Barré syndrome (GBS), Annexon Biosciences is embarking on another effort to improve treatment of the rare condition. Alongside a clinical data ...
Patients with Guillain- Barré syndrome (GBS) face a rare and heterogeneous disorder of the peripheral nervous system that is often triggered by preceding infections and causes severe muscle weakness.
Guillain-Barre syndrome (GBS) is an inflammatory disease that affects the nerves. It is thought to be an autoimmune disorder, and while the cause is not fully understood, it often arises after a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results